Literature DB >> 32205151

Sigma receptor-induced heavy drinking in rats: Modulation by the opioid receptor system.

Marta Valenza1, Angelo Blasio1, Alyssa DiLeo2, Pietro Cottone1, Valentina Sabino3.   

Abstract

Alcohol use disorder (AUD) is a major cause of morbidity and mortality worldwide, for which new efficacious treatments are necessary. The opioid receptor system is a mediator of the rewarding effects of alcohol; in particular, while activation of μ opioid receptors enhances ethanol intake in rodents, opioid-receptor antagonists, such as naloxone and naltrexone, reduce its pleasurable and reinforcing effects, thereby decreasing alcohol. Sigma receptors (Sig-Rs) have been proposed as modulators of the effects of alcohol and, therefore, as a potential new pharmacological target for AUD. Somewhat analogously to μ opioid ligands, SigR agonists increase, while SigR antagonists decrease alcohol intake in animal models of excessive alcohol drinking. However, a potential cross-talk between these two receptor systems in relation to alcohol consumption has so far not been investigated. Here, we addressed this question pharmacologically, by testing the effects of either activating or inhibiting opioid receptors on the heavy alcohol drinking induced by chronic stimulation of SigR in alcohol-preferring rats. We found that the opioid receptor agonist morphine, which per se increases ethanol intake, at a sub-threshold dose reduces the binge-like drinking induced by the repeated treatment with the SigR agonist 1,3-di-o-tolylguanidine (DTG); conversely, the opioid receptor antagonist naltrexone, which per se reduces ethanol intake, at a sub-threshold dose potentiates the DTG-induced binge-like drinking. Our data show a cross-talk between the opioid and SigR systems relevant to the modulation of alcohol drinking, which provides important insights into the neurobiology of AUD and may lead to the development of novel therapies, either standalone or in combination.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Addiction; Alcohol OR ethanol; Animal model; Binge; Morphine; Naltrexone; Rat; Self-administration

Mesh:

Substances:

Year:  2020        PMID: 32205151      PMCID: PMC9551643          DOI: 10.1016/j.pbb.2020.172914

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.697


  125 in total

1.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

3.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

Review 4.  Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder.

Authors:  George F Koob
Journal:  Curr Top Behav Neurosci       Date:  2013

5.  Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Luca Steardo; George F Koob; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2009-05-14       Impact factor: 4.530

6.  Selective antagonism of opioid analgesia by a sigma system.

Authors:  C C Chien; G W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

7.  Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats.

Authors:  Dong Ji; Nicholas W Gilpin; Heather N Richardson; Catherine L Rivier; George F Koob
Journal:  Behav Pharmacol       Date:  2008-02       Impact factor: 2.293

Review 8.  Animal models of motivation for drinking in rodents with a focus on opioid receptor neuropharmacology.

Authors:  George F Koob; Amanda J Roberts; Brigitte L Kieffer; Charles J Heyser; Simon N Katner; Roberto Ciccocioppo; Friedbert Weiss
Journal:  Recent Dev Alcohol       Date:  2003

Review 9.  Sigma Receptors and Substance Use Disorders.

Authors:  Valentina Sabino; Callum Hicks; Pietro Cottone
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 3.650

Review 10.  Role of Sigma Receptors in Alcohol Addiction.

Authors:  Sema G Quadir; Pietro Cottone; Valentina Sabino
Journal:  Front Pharmacol       Date:  2019-06-14       Impact factor: 5.810

View more
  4 in total

1.  Novel Highly Potent and Selective Sigma1 Receptor Antagonists Effectively Block the Binge Eating Episode in Female Rats.

Authors:  Carlo Cifani; Emanuela Micioni Di Bonaventura; Luca Botticelli; Fabio Del Bello; Gianfabio Giorgioni; Pegi Pavletić; Alessandro Piergentili; Wilma Quaglia; Alessandro Bonifazi; Dirk Schepmann; Bernhard Wünsch; Giulio Vistoli; Maria Vittoria Micioni Di Bonaventura
Journal:  ACS Chem Neurosci       Date:  2020-09-21       Impact factor: 4.418

2.  Diverse saturated heterocycles from a hydroacylation/conjugate addition cascade.

Authors:  Ndidi U N Iwumene; Daniel F Moseley; Robert D C Pullin; Michael C Willis
Journal:  Chem Sci       Date:  2022-01-19       Impact factor: 9.825

3.  Editorial: Kappa opioid receptors revealed: Disentangling the pharmacology to open up new therapeutic strategies.

Authors:  Wendy Margaret Walwyn; Marta Valenza
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

4.  Antagonism of Sigma-1 receptor blocks heavy alcohol drinking and associated hyperalgesia in male mice.

Authors:  Sema G Quadir; Sean M Tanino; Yasmine N Sami; Margaret A Minnig; Malliga R Iyer; Kenner C Rice; Pietro Cottone; Valentina Sabino
Journal:  Alcohol Clin Exp Res       Date:  2021-07-05       Impact factor: 3.928

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.